174 related articles for article (PubMed ID: 35857506)
1. ZMYND8 is a master regulator of 27-hydroxycholesterol that promotes tumorigenicity of breast cancer stem cells.
Luo M; Bao L; Chen Y; Xue Y; Wang Y; Zhang B; Wang C; Corley CD; McDonald JG; Kumar A; Xing C; Fang Y; Nelson ER; Wang JE; Wang Y; Luo W
Sci Adv; 2022 Jul; 8(28):eabn5295. PubMed ID: 35857506
[TBL] [Abstract][Full Text] [Related]
2. Suppression of poised oncogenes by ZMYND8 promotes chemo-sensitization.
Mukherjee S; Adhikary S; Gadad SS; Mondal P; Sen S; Choudhari R; Singh V; Adhikari S; Mandal P; Chaudhuri S; Sengupta A; Lakshmanaswamy R; Chakrabarti P; Roy S; Das C
Cell Death Dis; 2020 Dec; 11(12):1073. PubMed ID: 33323928
[TBL] [Abstract][Full Text] [Related]
3. Dual histone reader ZMYND8 inhibits cancer cell invasion by positively regulating epithelial genes.
Basu M; Sengupta I; Khan MW; Srivastava DK; Chakrabarti P; Roy S; Das C
Biochem J; 2017 May; 474(11):1919-1934. PubMed ID: 28432260
[TBL] [Abstract][Full Text] [Related]
4. YB-1 transforms human mammary epithelial cells through chromatin remodeling leading to the development of basal-like breast cancer.
Davies AH; Reipas KM; Pambid MR; Berns R; Stratford AL; Fotovati A; Firmino N; Astanehe A; Hu K; Maxwell C; Mills GB; Dunn SE
Stem Cells; 2014 Jun; 32(6):1437-50. PubMed ID: 24648416
[TBL] [Abstract][Full Text] [Related]
5. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
6. AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells.
Asiedu MK; Beauchamp-Perez FD; Ingle JN; Behrens MD; Radisky DC; Knutson KL
Oncogene; 2014 Mar; 33(10):1316-24. PubMed ID: 23474758
[TBL] [Abstract][Full Text] [Related]
7. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
8. A novel role of tumor suppressor ZMYND8 in inducing differentiation of breast cancer cells through its dual-histone binding function.
Mukherjee S; Sen S; Adhikary S; Sengupta A; Mandal P; Dasgupta D; Chakrabarti P; Roy S; DAS C
J Biosci; 2020; 45():. PubMed ID: 31965980
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-induced circSTT3A enhances serine synthesis and promotes H3K4me3 modification to facilitate breast cancer stem cell formation.
Xu M; Liu X; Zhou X; Qin Y; Yang L; Wen S; Qiu Y; Chen S; Tang R; Guo Y; Liu M; Sun Y
Pharmacol Res; 2023 Nov; 197():106964. PubMed ID: 37865128
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
11. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.
Fritz AJ; Hong D; Boyd J; Kost J; Finstaad KH; Fitzgerald MP; Hanna S; Abuarqoub AH; Malik M; Bushweller J; Tye C; Ghule P; Gordon J; Frietze S; Zaidi SK; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2020 Oct; 235(10):7261-7272. PubMed ID: 32180230
[TBL] [Abstract][Full Text] [Related]
12. Essential role of miR-200c in regulating self-renewal of breast cancer stem cells and their counterparts of mammary epithelium.
Feng ZM; Qiu J; Chen XW; Liao RX; Liao XY; Zhang LP; Chen X; Li Y; Chen ZT; Sun JG
BMC Cancer; 2015 Sep; 15():645. PubMed ID: 26400441
[TBL] [Abstract][Full Text] [Related]
13. Prolyl isomerase Pin1 acts downstream of miR200c to promote cancer stem-like cell traits in breast cancer.
Luo ML; Gong C; Chen CH; Lee DY; Hu H; Huang P; Yao Y; Guo W; Reinhardt F; Wulf G; Lieberman J; Zhou XZ; Song E; Lu KP
Cancer Res; 2014 Jul; 74(13):3603-16. PubMed ID: 24786790
[TBL] [Abstract][Full Text] [Related]
14. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
15. Targeting Breast Cancer Stem Cells.
Zhang L; Chen W; Liu S; Chen C
Int J Biol Sci; 2023; 19(2):552-570. PubMed ID: 36632469
[TBL] [Abstract][Full Text] [Related]
16. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
17. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin.
Kai M; Kanaya N; Wu SV; Mendez C; Nguyen D; Luu T; Chen S
Breast Cancer Res Treat; 2015 Jun; 151(2):281-94. PubMed ID: 25904215
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced adenosine A2B receptor expression mediates epigenetic regulation of pluripotency factors and promotes breast cancer stemness.
Lan J; Wei G; Liu J; Yang F; Sun R; Lu H
Theranostics; 2022; 12(6):2598-2612. PubMed ID: 35401817
[No Abstract] [Full Text] [Related]
19. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics.
Dang H; Ding W; Emerson D; Rountree CB
BMC Cancer; 2011 Sep; 11():396. PubMed ID: 21929801
[TBL] [Abstract][Full Text] [Related]
20. Disruption of IFN-I Signaling Promotes HER2/Neu Tumor Progression and Breast Cancer Stem Cells.
Castiello L; Sestili P; Schiavoni G; Dattilo R; Monque DM; Ciaffoni F; Iezzi M; Lamolinara A; Sistigu A; Moschella F; Pacca AM; Macchia D; Ferrantini M; Zeuner A; Biffoni M; Proietti E; Belardelli F; Aricò E
Cancer Immunol Res; 2018 Jun; 6(6):658-670. PubMed ID: 29622580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
